EUVIMEDEUVIMED entdecken
Open Access

Chemoembolization as first-line treatment for hepatocellular carcinoma invading segmental portal vein with tumour burden limited to a monosegmental level

Hyeonseung Hwang, Jin Hyoung Kim iD, Eunbyeol Ko, Jeong-Yeon Kim, Heung-Kyu Ko, Dong Il Gwon, Ji Hoon Shin, Gun Ha Kim, Hee Ho Chu

British Journal of Radiology · 2024

DOI: 10.1093/bjr/tqae052 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Radiology, 2024. Verfasst von Hyeonseung Hwang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 138-736, Korea. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Chemoembolization, Therapeutic, Liver Neoplasms, Portal Vein. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the safety and effectiveness of chemoembolization for hepatocellular carcinoma (HCC) with portal vein tumour thrombosis (PVTT) confined to a monosegment of the liver.

Methods

A total of 192 treatment-naive patients who received chemoembolization between March 2008 and January 2023 as a first-line treatment for locally advanced HCC with PVTT limited to a monosegment were retrospectively analysed. Overall survival (OS) and the identification of pretreatment risk factors related to OS were investigated using Cox regression analysis. Complications, radiologic tumour response, and progression-free survival (PFS) following chemoembolization were investigated.

Results

After chemoembolization, the 1-, 3-, and 5-year OS rates were 86%, 48%, and 39%, respectively, and the median OS was 33 months. Multivariable analyses revealed four significant pretreatment risk factors: infiltrative HCC (P = .02; HR, 1.60), beyond the up-to-11 criteria (P = .002; HR, 2.26), Child-Pugh class B (P = .01; HR, 2.35), and serum AFP ≥400 ng/mL (P = .01; HR, 1.69). The major complication rate was 5%. Of the 192 patients, 1 month after chemoembolization, 35% achieved a complete response, 47% achieved a partial response, 11% had stable disease, and 7% showed progressive disease. The median PFS after chemoembolization was 12 months.

Conclusions

Chemoembolization shows high safety and efficiency, and contributes to improved survival in patients with HCC with PVTT confined to a monosegment. Four risk factors were found to be significantly associated with improved survival rates after chemoembolization in patients with HCC with PVTT confined to a monosegment. Advances in knowledge (1) Although systemic therapy with a combination of atezolizumab and bevacizumab (Atezo-Bev) is recommended as the first-line treatment when HCC invades the portal vein, chemoembolization is not infrequently performed in HCC cases in which tumour burden is limited. (2) Our study cohort (n=192) had a median OS of 33 months and a 5% major complication rate following chemoembolization, findings in the range of candidates typically accepted as ideal for chemoembolization. Thus, patients with HCC with PVTT confined to a monosegment may be good candidates for first-line chemoembolization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsPortal VeinHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultTumor BurdenTreatment OutcomeAged, 80 and overRisk Factors

Stichwörter der Autor:innen

BCLC stagechemoembolizationhepatocellular carcinomaportal vein tumour thrombosis

Autor:innen und Institutionen

  • Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 138-736, Korea.

ORCID-Profile: Jin Hyoung Kim

Zitieren

APA

Hwang, H., Kim, J. H., Ko, E., Kim, J. Y., Ko, H. K., Gwon, D. I., Shin, J. H., Kim, G. H., & Chu, H. H. (2024). Chemoembolization as first-line treatment for hepatocellular carcinoma invading segmental portal vein with tumour burden limited to a monosegmental level. British Journal of Radiology. https://doi.org/10.1093/bjr/tqae052

Vancouver

Hwang H, Kim JH, Ko E, Kim JY, Ko HK, Gwon DI, et al. Chemoembolization as first-line treatment for hepatocellular carcinoma invading segmental portal vein with tumour burden limited to a monosegmental level. British Journal of Radiology. 2024. doi:10.1093/bjr/tqae052

BibTeX
@article{Hwang2024,
  author = {Hwang, Hyeonseung and Kim, Jin Hyoung and Ko, Eunbyeol and Kim, Jeong-Yeon and Ko, Heung-Kyu and Gwon, Dong Il and Shin, Ji Hoon and Kim, Gun Ha and Chu, Hee Ho},
  title = {Chemoembolization as first-line treatment for hepatocellular carcinoma invading segmental portal vein with tumour burden limited to a monosegmental level},
  journal = {British Journal of Radiology},
  year = {2024},
  doi = {10.1093/bjr/tqae052}
}
Kostenlos starten →